Circio logoCircio logo

  • About
    About
    Close
      • About Circio
      • Pipeline
      • Management Team
      • Board of Directors
      • Careers
  • circRNA
    circRNA
    Close
      • Circio AB
      • circVec platform
  • Clinical programs
    Clinical programs
    Close
      • ONCOS-102
      • KRAS program
      • Publications
  • Partnering
  • Investors
    Investors
    Close
      • Press releases
      • Events
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
      • Contact
  • Media
    Media
    Close
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    Contacts
    Close
      • Offices
      • Investors & Media
    • About
      • About Circio
      • Our pipeline
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
    • circRNA
      • Circio AB
      • circVec platform
    • Clinical programs
      • ONCOS-102
      • KRAS program
      • Publications
    • Partnering
      • Partnering
    • Investors
      • Press releases
      • Events
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Articles of Association
      • Contact
      • Subscribe
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media
    All press releases
    • Press releases - Regulatory
    • Press releases - Non-regulatory
    2022
    • 2023
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • All years
    All subjects
    • Corporate news
    • Other
    December 22, 2022
    Press release - Non-regulatory

    Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed

    December 20, 2022
    Press release - Regulatory

    Targovax ASA issues options to employees

    December 15, 2022
    Press release - Non-regulatory

    Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer

    December 7, 2022
    Press release - Non-regulatory

    Targovax to present and attend at upcoming conferences

    November 10, 2022
    Press release - Non-regulatory

    Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement

    November 3, 2022
    Press release - Regulatory

    Targovax ASA: Third quarter 2022 results

    October 26, 2022
    Press release - Regulatory

    Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November

    October 20, 2022
    Press release - Non-regulatory

    The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info

    October 20, 2022
    Press release - Non-regulatory

    The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research

    October 5, 2022
    Press release - Non-regulatory

    The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting

    September 27, 2022
    Press release - Non-regulatory

    Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA

    September 26, 2022
    Press release - Non-regulatory

    Reminder: Targovax to host Investor Event 27 September

    September 19, 2022
    Press release - Non-regulatory

    Targovax to host Investor Event: Meet the Management on 27 September

    September 12, 2022
    Press release - Non-regulatory

    Targovax to present at upcoming conferences

    August 18, 2022
    Press release - Regulatory

    Targovax ASA: Second quarter and first half year 2022 results

    August 11, 2022
    Press release - Non-regulatory

    Targovax ASA: Invitation to Targovax’s second quarter and first half 2022 presentation, Thursday 18 August

    July 4, 2022
    Press release - Regulatory

    Targovax: Completion of drop-down demerger

    June 23, 2022
    Press release - Non-regulatory

    Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA

    June 23, 2022
    Press release - Non-regulatory

    Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA

    June 7, 2022
    Press release - Regulatory

    Targovax ASA: Registration of share capital increase following settlement of restricted stock units and exercise of employee options

    May 31, 2022
    Press release - Regulatory

    Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs

    May 31, 2022
    Press release - Regulatory

    Targovax ASA: Exercise of options, settlement of restricted stock units and resolutions to increase the share capital

    May 27, 2022
    Press release - Non-regulatory

    Targovax announces publication of the two abstracts accepted for poster presentation at ASCO 2022

    May 12, 2022
    Press release - Regulatory

    Targovax ASA: First quarter 2022 results

    May 11, 2022
    Press release - Regulatory

    Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial

    May 11, 2022
    Press release - Non-regulatory

    Targovax to present at upcoming conferences

    May 10, 2022
    Press release - Non-regulatory

    Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma

    May 3, 2022
    Press release - Non-regulatory

    Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May

    April 28, 2022
    Press release - Non-regulatory

    Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO

    April 26, 2022
    Press release - Non-regulatory

    Targovax to present at 5th Neoantigen Summit Europe in Amsterdam

    April 21, 2022
    Press release - Non-regulatory

    Targovax ASA announces the appointment of two new Board Directors

    April 20, 2022
    Press release - Regulatory

    Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

    April 20, 2022
    Press release - Regulatory

    Targovax ASA: Minutes from the Annual General Meeting

    March 30, 2022
    Press release - Regulatory

    Notice of Annual General Meeting

    March 14, 2022
    Press release - Regulatory

    Targovax – Proposal to implement a drop-down demerger

    March 9, 2022
    Press release - Regulatory

    Targovax ASA: Annual Report 2021

    March 9, 2022
    Press release - Non-regulatory

    Targovax ASA: Poster presentation at the AACR Annual Meeting

    March 8, 2022
    Press release - Regulatory

    Targovax ASA: Registration of share capital increases following exercise of options

    March 7, 2022
    Press release - Regulatory

    Targovax ASA: GRANT OF SHARE OPTIONS TO NEW CFO

    March 7, 2022
    Press release - Non-regulatory

    Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™

    March 2, 2022
    Press release - Regulatory

    Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs

    March 2, 2022
    Press release - Regulatory

    Targovax ASA: Exercise of options under LTI program, settlement of RSUs and resolution to increase the share capital

    February 28, 2022
    Press release - Regulatory

    Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer

    February 17, 2022
    Press release - Regulatory

    Targovax ASA: Fourth quarter 2021 results

    February 9, 2022
    Press release - Regulatory

    Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February

    February 1, 2022
    Press release - Non-regulatory

    Targovax inngår forskningssamarbeid med Karolinska Institutet (Norwegian)

    February 1, 2022
    Press release - Regulatory

    Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration

    January 17, 2022
    Press release - Non-regulatory

    Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan

    January 12, 2022
    Press release - Regulatory

    Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway

    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@circio.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@circio.com
    (+47) 922 61 624
    • PRINT
    • STAY CONNECTED
    • Cookies
    • Privacy policy